| Name | Title | Contact Details |
|---|
Abraxis Oncology is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Social Media Commenting Policy Welcome! Whitman-Walker maintains social media channels as a service to our supporters who wish to keep updated on news from WWH and possibly share information with one another. We are glad to have you join us! We ...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
PBM consulting, provider nnetwork strategies, rebate benchmarking, global drug sourcing, client pricing, market assessments, MAC management, rebate aggregation.
Fifty 50 Pharmacy is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.